The results look pretty good but they had a large (total 55% of total enrollment) dropout rate. About a third of the dropoute were labeled as "Consent Withdrawal", though. I am not sure what to make of that.
The figures to look at are the "EOD"(3x/wk) and "TW"(2x/wk) efficacy numbers, because this is where CJC's primary advantage over the AMLN product lies.
I am taking the weight-loss numbers with a grain of salt, because of the prevalence of nausea in the study.
The price should come back up, and if it hits ~12US I will try to sell, probably to re-enter once they are on the NAZ
Market Data 
Markets 
AI
